Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
The De-ESCALaTE HPV trial confirmed the dominance of cisplatin over cetuximab for tumour control in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Here, we present the analysis of health-related quality of life (HRQoL), resource use, and health care costs in the trial, as well as complete 2-year survival and recurrence.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: David A. Jones, Pankaj Mistry, Matthew Dalby, Tessa Fulton-Lieuw, Anthony H. Kong, Janet Dunn, Hisham M. Mehanna, Alastair M. Gray Tags: Original Research Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Erbitux | Genital Warts | Health Management | Human Papillomavirus (HPV) | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma